Statistics from Altmetric.com
The implications of confirmed de novo pathogenic mutations in SOD1 are far-reaching for current clinical practice and future genetic research.
Progress has been made in the study of amyotrophic lateral sclerosis (ALS) genetics in recent years but there remains debate regarding the role of mutations which develop de novo in a patient, rather than being inherited from one or both parents. Theoretically, such mutations should occur but relatively few are reported. The mutation rate is estimated at 1.8×10−8 per nucleotide per generation,1 and therefore all individuals must carry de novo genetic changes. Moreover, ALS-associated mutations are not embryonically lethal and so there is no obvious reason why de novo forms of such mutations should not be present in patients with ALS. Occurrence of de novo mutations could explain minimal or even absent family history for patients carrying mutations which otherwise behave …
Contributors JC-K conceived and drafted the manuscript.
Funding This work was supported by Wellcome Trust (216596/Z/19/Z).
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.